Enzo Biochem Inc. (NYSE:ENZ) today announced that its Enzo Clinical Labs subsidiary and Massachusetts-based Nuclea Biotechnologies, Inc. have entered into a non-exclusive distribution agreement to market Nuclea’s non-invasive HER-2/neu serum test, a key assay in the monitoring of metastatic breast cancer.
This blood test facilitates the monitoring and treatment decisions of women with metastatic breast cancer that overexpresses the HER-2/neu protein in the tumor. Individuals with this condition tend to have a worse prognosis and a more aggressive disease that can resist certain types of chemotherapy. The test measures the portion of HER-2/neu protein that lies outside the surface of the cell and being released into the blood stream, allowing for more informed treatment decisions for a number of women who may not be responding to breast cancer treatment or may be at risk for metastatic cancer and need revised treatment plans.
“We are pleased to partner with Nuclea Biotechnologies in marketing this key assay,” said Cynthia Bowman, MD, Medical Director of Enzo Clinical Labs. “Offering the serum HER2/neu testing ties in with our expanding program of developing and making available high value esoteric testing, especially in the area of women’s health, and providing our physician clients with yet another tool with which to customize a woman’s assessment and treatment. Moreover, the use of this assay in treatment monitoring may open up our services to the Pharmaceutical market.”
“Our agreement with Enzo will serve as a catalyst for greater market reach of our serum HER-2/neu test,” said Patrick Muraca, President and CEO of Nuclea. “Enzo Labs’ long standing reputation as a leader in the delivery of high value diagnostics make them an excellent partner to increase the market’s recognition and use of this important breast cancer assay.”
Utilizing the HER-2/neu blood test while monitoring the disease’s progression will enable physicians to better adapt, combine therapies and change treatment protocols. Studies have demonstrated that use of combination chemotherapy regimens provides a statistically significant advantage for survival and tumor response in women with metastatic breast cancer.